Immuneering’s Pancreatic Cancer Trial Data to Debut at ESMO 2026…

Event summary

Immuneering’s Phase 3 MAPKeeper 301 trial data for atebimetinib in pancreatic cancer accepted for poster presentation at ESMO 2026.
Presentation scheduled for October 25, 2026, in Madrid, Spain, with full abstracts published October 19, 2026.
Trial evaluates atebimetinib + modified gemcitabine/nab-paclitaxel vs. standard chemotherapy in first-line pancreatic cancer.
Lead author is Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center.

The big picture

Immuneering’s ESMO presentation comes as pancreatic cancer remains one of oncology’s most challenging indications, with limited treatment advances. The company’s focus on Deep Cyclic Inhibitors represents a strategic pivot from conventional MAPK inhibitors, aiming to address tumor resistance and cachexia. Success in this trial could position Immuneering as a key player in precision oncology, though competition from established players and emerging therapies remains intense.

What we're watching

Trial Outcomes: Whether Phase 3 data confirms atebimetinib’s survival benefits in pancreatic cancer, validating its differentiated mechanism.
Regulatory Pathway: The pace at which Immuneering advances atebimetinib toward potential approval, given the aggressive trial timeline.
Competitive Positioning: How Immuneering differentiates itself in the crowded pancreatic cancer treatment landscape.